Goods & Services

Pharmaceutical and medicinal preparations and substances; vaccines.

Goods & Services

Pharmaceutical and medicinal preparations and substances; vaccines.

Abstract

Provided herein are 3′ and 5′ UTRs that provide an amount, duration, or both of protein expression from a recombinant RNA. Compositions of matter, methods, or uses of said 3′ and 5′ UTRs are provided. Provided herein are RNA segments that encode a SARS-CoV-2 omicron spike protein, which provide for omicron-strain-specific immunogenic compositions. Compositions of matter, methods, or uses of said RNA segments that encode a SARS-CoV-2 omicron spike protein are provided.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/51 - Nanocapsules
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

Modified HCMV gB proteins in a pre-fusion conformation, compositions comprising such proteins, and uses thereof.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/39 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts
• C12N 9/88 - Lyases (4.)

Goods & Services

Pharmaceutical and medicinal preparations and substances; vaccines.

Goods & Services

(1) Pharmaceutical and medicinal preparations and substances; vaccines.

Goods & Services

(1) Pharmaceutical and medicinal preparations and substances; vaccines.

Goods & Services

Pharmaceutical and medicinal preparations and substances; vaccines.

Abstract

A method for immunizing a subject in need thereof against Neisseria gonorrhoeaeby administering an immunogenic composition comprising meningococcal outer membrane vesicles (OMVs).

IPC Classes  ?

• A61K 39/095 - Neisseria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/116 - Polyvalent bacterial antigens
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

The present invention is in the field of treating and/or preventing viral infections. In particular, the present invention relates to immunogenic or pharmaceutical compositions comprising self-replicating RNA molecules that encode influenza virus antigens for treating and/or preventing influenza infections.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Goods & Services

(1) Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, pulmonary, cardiorenal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the treatment of blood diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle cell disease, anaemia, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, ligament injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin infections namely acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of irritable bowel disorders and symptoms, digestive disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrhea and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids and Leiomyoma; pharmaceutical preparations and substances for use in urology, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, cirrhosis, cholestatic pruritus and primary biliary cholangitis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia and psychoses; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; Allergy medications; Vaccines for human use; pharmaceutical preparations for the treatment of central nervous system and neurological diseases and disorders namely Parkinsons Disease, Alzheimers Disease, Huntingtons Disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of nephrological related diseases and disorders

Goods & Services

Pharmaceutical preparations and substances; medicinal preparations and substances; vaccines.

Abstract

The invention provides an immunogenic composition comprising OMVs and (a) acellular pertussis antigen, (b) a tetanus toxoid and (c) a diphtheria toxoid, wherein the OMVs are derived from Bordetella pertussis. The invention also provides compositions for use in a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/04 - Antibacterial agents

Abstract

Candida albicansCandida albicans') protein. The modified Sap2 protein can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.

IPC Classes  ?

• C12N 9/58 - Proteinases derived from fungi
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C12P 21/00 - Preparation of peptides or proteins
• C12N 9/10 - Transferases (2.)

Abstract

Candida albicansCandida albicans) protein. The modified Als3 protein can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/10 - Antimycotics
• C07K 14/40 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts from Candida
• C07K 16/14 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from fungi, algae or lichens
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus

Abstract

The present invention relates to immunogenic compositions comprising outer membrane vesicles (OMVs) adsorbed to an aluminium hydroxide adjuvant, whereby the aluminium hydroxide adjuvant is quenched. The present invention also relates to the use of the immunogenic compositions for providing protection against diseases caused by Gram-negative bacteria. The present invention also relates to a method for reducing particle aggregation and/or average particle diameter in compositions comprising OMVs and an aluminium hydroxide adjuvant.

IPC Classes  ?

• A61K 39/112 - SalmonellaShigella
• A61P 31/04 - Antibacterial agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient

Abstract

The present invention relates to conjugates comprising polysaccharides comprising 3- deoxy-D-manno-actulosonic acid (KDO) moieties, particularly conjugates produced using random conjugation methods, methods for preparing such conjugates, immunogenic compositions and vaccines comprising the conjugates, and methods of treatment or medical uses using the compositions and vaccines.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 39/112 - SalmonellaShigella
• A61P 31/04 - Antibacterial agents
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

S. entericaS.S. Paratyphi A bacterium comprising modified lipid A.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61K 39/112 - SalmonellaShigella
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to immunogenic compositions comprising antigens from Salmonella enterica serovar Typhimurium (S. Typhimurium), Salmonella enterica serovar Enteritidis (S. Enteritidis), and Salmonella enterica serovar Typhi (S. Typhi). The present invention further relates to methods and uses of compositions comprising GMMA for boosting an immune response to an S. Typhi antigen, vaccines comprising the immunogenic compositions and methods and uses of the immunogenic compositions.

IPC Classes  ?

• A61K 39/112 - SalmonellaShigella
• A61P 31/04 - Antibacterial agents

Abstract

The present invention provides lyophilised pharmaceutical compositions and processes of making said lyophilised pharmaceutical compositions. More particularly, the present invention provides lyophilised pharmaceutical compositions comprising lipid nanoparticles encapsulating a nucleic acid payload wherein the lyophilised pharmaceutical composition is in the form of a plurality of lyophilised beads (LyoBeads) and processes for making said compositions. The present invention further provides the use of said lyophilised pharmaceutical compositions in medicine.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/51 - Nanocapsules
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Abstract

The present disclosure provides T7 RNA polymerase variants, the use of which increases transcription efficiency and improves the quality and yield of the enzyme. Also provided are polynucleotides encoding the T7 RNA polymerase variants, host cells capable of expressing the T7 RNA polymerase variants, and methods of using the T7 RNA polymerase variants for high-efficiency transcription.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

Described are mutant, human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.

IPC Classes  ?

• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Goods & Services

Pharmaceutical and medicinal preparations and substances; vaccines.

Abstract

A method of immunizing a human female subject to decrease the risk of Group B Streptococcus (GBS) disease in an infant born to the subject, by providing a priming dose of a GBS vaccine and, more than thirty days after the priming dose, providing a boosting dose of a GBS vaccine.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/04 - Antibacterial agents

Abstract

inter alia inter alia, an RSV-F protein comprising at least two mutations relative to SEQ ID NO: 1 or 3 within a region of the protein corresponding to positions 474-523 of SEQ ID NO: 1 or 3; wherein the at least two mutations introduce, through substitution or insertion, a pair of C residues into the region, which form a disulphide bond.

IPC Classes  ?

• C07K 14/135 - Respiratory syncytial virus
• C12N 15/45 - Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61P 31/14 - Antivirals for RNA viruses

Abstract

RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.

IPC Classes  ?

• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/12 - Antivirals
• A61P 37/04 - Immunostimulants
• C12N 15/86 - Viral vectors

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of amaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious disease; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Abstract

Provided herein are methods, immunogenic combinations, immunogenic compositions, and uses thereof directed to co-administration of an immunogenic composition comprising a recombinant RSV antigen comprising a soluble F protein comprising at least one modification that stabilizes the prefusion conformation of the F protein; and an immunogenic composition comprising at least one glycoconjugate from each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/09 - Streptococcus
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.

IPC Classes  ?

• C07K 14/045 - Cytomegalovirus
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus

Abstract

The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/20 - Antivirals for DNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Goods & Services

(1) Vaccines for human use.

Goods & Services

Pharmaceutical and medicinal preparations and substances; vaccines.

Abstract

The present invention relates to a process for the production of purified O-polysaccharide-Exoprotein A (O-EPA) bioconjugates. In particular, the process comprises a purification of said bioconjugate comprising the steps of a first anion exchange chromatography prior to a hydroxyapatite chromatography followed by a hydrophobic interaction chromatography and subsequently a second anion exchange chromatography.

IPC Classes  ?

• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C07K 1/18 - Ion-exchange chromatography
• C07K 1/20 - Partition-, reverse-phase or hydrophobic interaction chromatography
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present invention relates to immunogenic compositions and their use in providing protection against illness caused by infection with Shigella. The immunogenic compositions comprise Shigella GMMA with particular doses of O-antigen.

IPC Classes  ?

• A61K 39/112 - SalmonellaShigella
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/04 - Antibacterial agents

Abstract

inter aliainter alia directed to immunogenic compositions for use in the treatment or prophylaxis of an infection with an Influenza virus, wherein the immunogenic composition comprises: (a) a first nucleic acid encoding a hemagglutinin (HA) antigen of a strain of a first subtype of Influenza A virus; (b) a second nucleic acid encoding a HA antigen of a strain of a second subtype of Influenza A virus; (c) a third nucleic acid encoding a HA antigen of a first strain of Influenza B virus; and (d) optionally, a fourth nucleic acid encoding a HA antigen of a second strain of Influenza B virus, wherein an immune response is elicited against HA antigens of said strains of first and second subtypes of Influenza A virus, said first and, optionally, second strains of Influenza B virus and at least one further HA antigen subtype of Influenza A virus, being different from any of the HA antigen subtypes of Influenza A virus encoded by a nucleic acid present in the composition.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention is inter alia directed to immunogenic compositions comprising: (a) a first hemagglutinin (HA) antigen or a first nucleic acid, suitably mRNA, encoding the first HA antigen wherein the first HA antigen is derived from a strain of subtype H3 of Influenza A virus; and (b) a second HA antigen or a second nucleic acid, suitably mRNA, encoding the second HA antigen wherein the second HA antigen is derived from a strain of subtype H1 of Influenza A virus, wherein the ratio of (a):(b) is comprised between 1.5:1 and 20:1. The present invention is also directed to vaccines and kits or kits-of-parts comprising such. Immunogenic compositions, vaccines and kits-of-parts provided herein are suitable for use as a medicament, in particular, for use in the treatment or prophylaxis of an infection with an Influenza virus, suitably an Influenza A and/or Influenza B.

IPC Classes  ?

• A61K 39/12 - Viral antigens

Abstract

Compositions and methods are provided for stabilization of RNA encapsulated by lipid nanoparticles during lyophilization. Novel lyophilization processes are provided. These techniques may be used to prevent the need for cold chain storage.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Improved methods for manufacturing a RNA by IVT and compositions for use therein are provided.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Goods & Services

(1) Pharmaceutical and medicinal preparations and substances; vaccines.

Abstract

The inventors have identified residues within variant 2 and variant 3 of meningococcal fHpb which can be modified to enhance their properties.

IPC Classes  ?

• C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/095 - Neisseria

Abstract

A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).

IPC Classes  ?

• A61K 39/108 - EscherichiaKlebsiella
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/04 - Antibacterial agents
• A61P 37/04 - Immunostimulants
• C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)
• C07K 19/00 - Hybrid peptides
• C12N 9/10 - Transferases (2.)

Abstract

inter alia inter alia, a recombinant nucleic acid encoding a respiratory syncytial virus fusion (RSV-F) protein comprising a cytoplasmic tail; wherein, relative to a cytoplasmic tail according to SEQ ID NO: 3 or 4, 2-20 residues are deleted from the cytoplasmic tail of the RSV-F protein.

IPC Classes  ?

• C12N 15/45 - Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
• C07K 14/135 - Respiratory syncytial virus
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present disclosure provides inter alia, a recombinant ribonucleic acid (RNA) encoding a respiratory syncytial virus fusion (RSV-F) protein comprising an F2 and an F1 domain; wherein the RSV-F protein further comprises, relative to a wild-type RSV-F sequence, the substitution of a residue for a C residue in both of the F2 and F1 domains.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present invention discloses a recombinant bacteriophage comprising a phage genome polynucleotide including a gene encoding a heterologous antigen protein(s) and a killing gene encoding a protein that is capable of killing a host bacterium. Such a recombinant bacteriophage is designed to prime a subject's immune response and to kill the bacterium that it infects such that the “prime and kill” bacteriophage provides two lines of protection against infectious disease.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/04 - Antibacterial agents
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/86 - Viral vectors
• C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors

Abstract

Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.

IPC Classes  ?

• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
• B01D 61/14 - UltrafiltrationMicrofiltration
• C07H 1/06 - SeparationPurification
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The invention relates to an immunization regimen whereby an infant is protected against respiratory syncytial virus (RSV) through administration of a first anti-RSV immune response inducing composition to his or her mother during pregnancy, followed by administration of a second anti-RSV immune response inducing composition to the infant after birth.

IPC Classes  ?

• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes an interferon effector.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/86 - Viral vectors

Abstract

The present invention provides lyophilised pharmaceutical compositions and methods of making said lyophilised pharmaceutical compositions. More particularly, the present invention provides lyophilised pharmaceutical compositions comprising nucleic acid and lipid carrier particles and methods of making said lyophilised pharmaceutical compositions. The provided lyophilised compositions have improved critical quality attributes (CQAs) and the provided methods prevent the need for a deep-freeze cold chain. The present invention further provides the use of said lyophilised pharmaceutical compositions in medicine.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.

IPC Classes  ?

• A61K 39/095 - Neisseria
• A61K 35/74 - Bacteria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/108 - EscherichiaKlebsiella
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

The present invention relates to compositions and methods for manufacturing an adjuvant comprising a saponin using a microfluidic device and to aspects thereof.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• B01F 23/41 - Emulsifying
• B01F 25/433 - Mixing tubes wherein the shape of the tube influences the mixing, e.g. mixing tubes with varying cross-section or provided with inwardly extending profiles
• B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
• B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions

Abstract

The present invention relates to a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.

IPC Classes  ?

• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present invention relates to the field of immunogenic compositions and vaccines, their manufacture, host cells which can be used in their manufacture and the use of such immunogenic compositions and vaccines in medicine. More particularly, it relates to an immunogenic composition comprising a Klebsiella pneumoniae O1v1 O-antigen polysaccharide conjugate, a Klebsiella pneumoniae O2a O-antigen polysaccharide conjugate, a Klebsiella pneumoniae O2afg O-antigen polysaccharide conjugate and a Klebsiella pneumoniae O3b O-antigen polysaccharide conjugate, wherein each of the Klebsiella pneumoniae O1v1, O2a, O2afg and O3b O-antigen polysaccharides are individually conjugated to a carrier protein (e.g. a detoxified Exotoxin A of Pseudomonas aeruginosa (EPA)) wherein the Klebsiella pneumoniae O3b O-antigen polysaccharide conjugate is present in said immunogenic composition at a higher saccharide dose than at least one of the Klebsiella pneumoniae O1v1 O-antigen polysaccharide conjugate, Klebsiella pneumoniae O2a O-antigen polysaccharide conjugate or Klebsiella pneumoniae O2afg O-antigen polysaccharide conjugate.

IPC Classes  ?

• A61K 39/108 - EscherichiaKlebsiella
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)

Abstract

The present invention relates to immunisation using carrier-formulated mRNA in conjunction with an adjuvant comprising a STING agonist, and to related aspects.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.

IPC Classes  ?

• A61K 39/112 - SalmonellaShigella
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 39/104 - Pseudomonas
• A61K 39/108 - EscherichiaKlebsiella
• A61K 39/385 - Haptens or antigens, bound to carriers
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria

Abstract

A process for engineering a host cell comprising the steps of a) integrating a first polynucleotide cassette including a first selection marker flanked by a first pair of recombination sites; b) removing the first selection marker by the action of a recombinase which recognises the first pair of recombination sites; c) integrating a second polynucleotide cassette including a second selection marker flanked by a second pair of recombination sites; and d) removing the second selection marker by the action of a recombinase which recognises the second pair of recombination sites. The first and second pairs of recombination sites have identical nucleic acid sequences within each pair, sharing 90-98% nucleic acid sequence identity. Also disclosed is a host cell genome polynucleotide comprising two recombinantly engineered regions, each adjacent to a single recombination site sharing 90-98% identity with each other and any additional recombination sites present in the host cell genome polynucleotide.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/10 - Transferases (2.)

Abstract

The present invention relates to liquid chromatography methods (e.g., HPLC) that facilitate high resolution separation of mRNA formulated in lipid nanoparticles (LNPs) from impurities. In aspects, the disclosure relates to a mobile phase with two or more eluents that separates constituents of a mixture into one or more peaks, wherein at least one of the peaks is a well- defined impurity peak that can be quantified to accurately determine the amount of the impurity in the mixture.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• B01D 15/16 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
• B01D 15/32 - Bonded phase chromatography, e.g. with normal bonded phase, reversed phase or hydrophobic interaction
• B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• G01N 30/02 - Column chromatography

Abstract

Provided are novel vaccines for prophylactic treatment of SARS-COV-2 infections and COVID-19 and methods of making the vaccines, wherein the vaccines contain an oil-in-water emulsion comprising tocopherol and squalene.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 5/07 - Animal cells or tissues
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A potency release assay for measuring the potency of drug product composition comprising self-amplifying mRNA (SAM) that encodes at least one immunogenic polypeptide or at least one therapeutic peptide and a non-viral delivery system is described. In one embodiment the drug product is a vaccine comprising SAM and a non-viral delivery system such as SAM/lipid nanoparticle (LNP) delivery system, a Cationic Nanoemulsion (CNE) delivery system, or another SAM delivery system. It is demonstrated that the potency of a SAM drug product can be assessed in an in vitro system, at the RNA amplification stage (agnostic assay), by measuring the amount of double-stranded RNA (dsRNA) in cells which have been transfected with the SAM in the drug product. Thus, dsRNA can be used as a surrogate endpoint for potency. It is demonstrated that there is a very high correlation between total dsRNA in a cell culture transfected with the SAM and the potency of the SAM based drug product.

IPC Classes  ?

• C12Q 1/6804 - Nucleic acid analysis using immunogens
• G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
• G01N 15/10 - Investigating individual particles
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry

Abstract

The present invention relates to immunogenic compositions comprising Clostridioides difficile (C. difficile) immunogens. More particularly the present invention relates to immunogenic compositions comprising a first immunogen and a second immunogen the first immunogen comprising a C. difficile toxin A CROP domain fragment and a C. difficile toxin B CROP domain fragment and the second immunogen comprising a fragment of C. difficile toxin B which comprises at least 100 contiguous amino acids of the delivery and receptor binding domain (DRBD) of toxin B. The present invention further relates to nucleic acids encoding C. difficile polypeptides and the use of said immunogenic compositions and nucleic acids in medicine.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61K 39/08 - Clostridium, e.g. Clostridium tetani
• A61P 31/04 - Antibacterial agents

Abstract

The present invention provides improved RNA-LNP formulations with lower amounts of RNA adduct, As well as methods and uses to reduce the amount of RNA adduct in RNA- LNP formulations, in particular mRNA-LNP formulations.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 9/51 - Nanocapsules

Abstract

The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus

Abstract

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing against Neisseria meningitidis infection.

IPC Classes  ?

• C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
• A61K 39/095 - Neisseria
• A61P 31/04 - Antibacterial agents

Abstract

Modified meningococcal fHbp polypeptides with increased stability.

IPC Classes  ?

• C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
• A61K 39/095 - Neisseria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer campuses at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1 kDa and 3 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - DispersionsEmulsions
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

Immunogenic compositions comprising influenza A strain haemagglutinin antigens and polynucleotides encoding the antigens.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• C07K 14/11 - Orthomyxoviridae, e.g. influenza virus

Abstract

A composition for treating chronic hepatitis B infection comprising mRNA encoding a hepatitis B virus antigen, wherein the mRNA is encapsulated in a lipid nanoparticle (LNP).

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/12 - Antivirals
• C07K 14/74 - Major histocompatibility complex [MHC]
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Provided herein are RNA that: are collectively self-amplifying in an intracellular environment, comprise N1-methyl-pseudouridines and uridines, and have a mole percentage or mole proportion of the N1-methylpseudouridines to the total of the uridines and the Ni-methylpseudouridines or a mole ration of the N1-methylpseudouridines to the uridines.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention relates to carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 37/04 - Immunostimulants

Abstract

The present invention relates to a carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present invention relates to vaccination against respiratory syncytial virus (RSV), in particular to the use of a vaccine formulation comprising an RSV fusion (F) protein (RSV F protein) antigen and an adjuvant in methods of inducing an immune response and in methods of prevention of RSV infection and disease in older adults.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Goods & Services

Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders

Abstract

The present invention relates to influenza virus immunisation using at least one influenza HA stem polypeptide in conjunction with squalene emulsion adjuvants, and to related aspects.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 37/04 - Immunostimulants

Abstract

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions are described comprising conjugates of E. coli polysaccharide antigen O1, 02, 04, 06, 08, 015, 016, 018, 025, and 075 and further comprising 0153 or 021 or both 0153 and 021 covalently bound to a carrier protein for the prevention of invasive ExPEC disease.

IPC Classes  ?

• A61K 39/108 - EscherichiaKlebsiella
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 31/04 - Antibacterial agents

Abstract

The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present invention relates to the field of immunogenic compositions and the use of such compositions in medicine. More particularly, it relates to immunogenic compositions comprising an immunogenic polypeptide from non-typeable Haemophilus influenzae, a PE-PilA fusion protein, and optionally an immunogenic polypeptide of UspA2 from Moraxella catarrhalis, for use in subjects having chronic obstructive pulmonary disease (COPD), in particular for reducing the frequency of severe exacerbations (i.e. severe AECOPDs).

IPC Classes  ?

• A61K 39/102 - PasteurellaHaemophilus
• A61K 39/104 - Pseudomonas
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to the field of native outer membrane vesicles (nOMVs), particularly nOMVs having increased levels of lipoproteins on their surface and use of same in immunogenic compositions.

IPC Classes  ?

• A61K 39/095 - Neisseria
• C12N 9/14 - Hydrolases (3.)